ARS Pharmaceuticals, Inc.

Pharmaceutical Preparations

SPRY Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0001671858 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$473.37M
99,447,343 shares Covers every share class this company has on file.
Insiders on file
4
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$40.06M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
8.46%
insider-held value divided by market capitalisation

What ARS Pharmaceuticals, Inc. reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$84.28M
FY2025 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
-$171.30M
FY2025 a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
195
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at ARS Pharmaceuticals, Inc.

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against ARS Pharmaceuticals, Inc..
Insider Reported role Shares Value Last action
Officers 1
Sarina Tanimoto Other Executive 1,246,494 $7.01M S Open-market sale Aug 20, 2025 position reported
Officers who also sit on the board 2
Pratik Shah CEO 4,474,554 $25.15M G Bona fide gift Nov 12, 2025 position reported
Richard E Lowenthal CEO 1,196,494 $6.72M S Open-market sale Aug 21, 2025 position reported
Directors 1
Laura Shawver Board Member 210,346 $1.18M S Open-market sale Apr 7, 2025 position reported

Recent insider transactions

Of the 144 rows we hold, 0 are open-market purchases and 110 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for ARS Pharmaceuticals, Inc., newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Nov 12, 2025 Pratik Shah G Bona fide gift 250,000 $0.00 $0 SEC filing ↗
Nov 12, 2025 Pratik Shah G Bona fide gift 100,000 $0.00 $0 SEC filing ↗
Aug 21, 2025 Richard E Lowenthal S Open-market sale 50,000 $14.49 $724.5K SEC filing ↗
Aug 20, 2025 Sarina Tanimoto S Open-market sale 37,656 $14.09 $530.6K SEC filing ↗
Aug 19, 2025 Sarina Tanimoto S Open-market sale 12,344 $14.03 $173.2K SEC filing ↗
Apr 7, 2025 Laura Shawver S Open-market sale 50,002 $12.30 $615.0K SEC filing ↗
Apr 7, 2025 Laura Shawver M Option exercise or conversion 27,493 $4.85 $133.3K SEC filing ↗
Apr 7, 2025 Laura Shawver M Option exercise or conversion 22,509 $4.85 $109.2K SEC filing ↗
Mar 6, 2025 Laura Shawver M Option exercise or conversion 49,600 $4.85 $240.6K SEC filing ↗
Mar 6, 2025 Laura Shawver S Open-market sale 49,600 $11.21 $556.0K SEC filing ↗
Mar 5, 2025 Laura Shawver S Open-market sale 400 $11.00 $4.4K SEC filing ↗
Mar 5, 2025 Laura Shawver M Option exercise or conversion 400 $4.85 $1.9K SEC filing ↗
Feb 3, 2025 Laura Shawver M Option exercise or conversion 9,064 $3.15 $28.6K SEC filing ↗
Feb 3, 2025 Laura Shawver S Open-market sale 50,000 $12.31 $615.5K SEC filing ↗
Feb 3, 2025 Laura Shawver M Option exercise or conversion 40,936 $4.85 $198.5K SEC filing ↗
Jan 6, 2025 Laura Shawver S Open-market sale 50,000 $11.10 $555.0K SEC filing ↗
Jan 6, 2025 Laura Shawver M Option exercise or conversion 50,000 $3.15 $157.5K SEC filing ↗
Dec 17, 2024 Sarina Tanimoto S Open-market sale 50,000 $11.67 $583.5K SEC filing ↗
Dec 17, 2024 Sarina Tanimoto S Open-market sale 50,000 $11.67 $583.5K SEC filing ↗
Dec 17, 2024 Richard E Lowenthal S Open-market sale 50,000 $11.67 $583.5K SEC filing ↗
Dec 17, 2024 Richard E Lowenthal S Open-market sale 50,000 $11.67 $583.5K SEC filing ↗
Dec 10, 2024 Sarina Tanimoto S Open-market sale 50,000 $13.16 $658.0K SEC filing ↗
Dec 10, 2024 Sarina Tanimoto S Open-market sale 50,000 $13.17 $658.5K SEC filing ↗
Dec 10, 2024 Richard E Lowenthal S Open-market sale 50,000 $13.17 $658.5K SEC filing ↗
Dec 10, 2024 Richard E Lowenthal S Open-market sale 50,000 $13.16 $658.0K SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Corporate ownership links — 12 filers hold a position

Who owns ARS Pharmaceuticals, Inc.

Each row is one filer naming this company.

Funds, trusts and other companies file the same ownership forms that executives do. Everything below is taken from those filings, with the position exactly as the filing states it.

Do not add these figures together. 9 of the positions below were reported on filings shared by several filers at once.

Why the same shares appear twice

On a joint filing every named filer is listed against the whole position, so the same block of stock appears under each name. Those rows are marked joint.

Filers holding a position in ARS Pharmaceuticals, Inc.

Funds, trusts and companies that disclose an ownership position in ARS Pharmaceuticals, Inc..
Owner Reported role Shares Filed
DEERFIELD MANAGEMENT COMPANY, L.P. Director,Other,TenPercentOwner 9,774,508 joint
Deerfield Mgmt III, L.P. Director,Other,TenPercentOwner 9,774,508 joint
Deerfield Mgmt IV, L.P. Director,Other,TenPercentOwner 9,774,508 joint
Deerfield Private Design Fund III, L.P. Director,Other,TenPercentOwner 9,774,508 joint
Deerfield Private Design Fund IV, L.P. Director,Other,TenPercentOwner 9,774,508 joint
Pratik Shah Living Trust dated June 15, 2011 TenPercentOwner 7,490,404 joint
ORBIMED ADVISORS LLC Director,Other,TenPercentOwner 0 joint
OrbiMed Capital GP VI LLC Director,TenPercentOwner 0 joint
ORBIMED CAPITAL LLC Director,TenPercentOwner 0 joint
RA Capital Healthcare Fund LP Director,Other,TenPercentOwner
RA CAPITAL MANAGEMENT, L.P. Director,Other,TenPercentOwner
RA Capital Nexus Fund II, L.P. Director,TenPercentOwner

See the full ownership map — every entity that files as an owner of a US public company.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from ARS Pharmaceuticals, Inc.’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from ARS Pharmaceuticals, Inc.’s own SEC filings multiplied by the closing price we hold for the same stock.